Beijing Dongfang Biotech Co., Ltd.

Beijing Jingyitaixiang Technology Development Co. Ltd.

Shengmei Wen

Wen Tao Zhang

Yi Bai

Meng Xu

Xiaomin Li

Yanlu Zan

Shuang Pei

Wen Zhang

An anti-Epidermal Growth Factor Receptor (EGFR) and anti-Cluster-of-Differentiation (CD3) bispecific antibody and uses thereof are provided. The bispecific antibody can specifically bind to antigen epidermal growth factor receptor (EGFR) on tumor cell surface and antigen CD3 molecule on immune cell surface. The single-chain antibody (ScFv) of an anti-CD3 antibody is located at the C terminal of the constant region of the anti-EGFR antibody. Further provided are a preparation method of the bispecific antibody and clinical applications of the bispecific antibody. The bispecific antibody has high affinity, and is used for treating tumor diseases caused by high expression or abnormal expression of the EGFR and other diseases caused by other overexpression of the EGFR.

Anti-EGFR and anti-CD3 bispecific antibody and uses thereof

The application discloses an anti-Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) monoclonal antibody, an amino acid sequence comprising coded antibody variable regions and Complementarity-Determining Regions (CDR), the obtaining method, and application of monoclonal antibody. The anti-PCSK9 monoclonal antibodies are screened from a phage antibody library; affinity maturation is achieved by using a method that the phage antibody library is established by means of chain displacement; After screening the light chain CDR1, 2, 3 Mutant Library of monoclonal antibodies obtained from primary screening; monoclonal antibodies having high affinity are selected; then screening the mutant libraries of heavy chain CDR1, 2, 3 regions; and finally the monoclonal antibodies having high affinity are screened. The PCSK9 antibody obtained by the application has good affinity to PCSK9 and can inhibit the binding of PCSK9 with its ligand and can be used for treating dyslipidemia, cardiovascular and cerebrovascular diseases and thrombotic occlusion diseases.

Anti-PCSK9 monoclonal antibody

Growing community of inventors

Beijing, China

Shengmei Wen